After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer

Blueprint Medicines Corp BPMC announced proof-of-concept data from the Phase 1/2 SYMPHONY trial of BLU-945 for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

  • The data were shared at the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • The early readout from the phase 1/2 Symphony trial shows the first safety and clinical activity data.
  • Results from the higher dose group hint at tumor shrinkage too. One patient treated with 400 mg once daily experienced a partial response as of the March 9 cut-off date.
  • As for safety, common adverse events included nausea, headache, difficulty breathing and vomiting, among others. 
  • Blueprint did observe one incident of dose-limiting toxicity in a patient who experienced high levels of an enzyme called transaminases that can point to problems with the liver. 
  • The dose was interrupted, and the patient improved. Blueprint said that there were no study discontinuations.
  • Blueprint will initiate an additional cohort in the Symphony trial combining BLU-945 with AstraZeneca Plc's AZN Tagrisso (osimertinib) following disease progression on osimertinib.
  • The company announced a clinical supply agreement with AstraZeneca for work on the study and the early-stage Harmony program for BLU-701.
  • Price Action: BPMC shares traded lower by 3.46% at $67.18 on the last check Monday.

Posted In: BriefsBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.